Phosphorylation of the Ras-GRF1 Exchange Factor at Ser916/898 Reveals Activation of Ras Signaling in the Cerebral Cortex*

Huibin YangDagger , Desma CooleyDagger §, Julie E. LegakisDagger , Qingyuan Ge||, Rodrigo AndradeDagger **, and Raymond R. MattinglyDagger Dagger Dagger §§

From the Departments of Dagger  Pharmacology and ** Psychiatry and Behavioral Neurosciences and the Dagger Dagger  Program in Molecular Biology and Genetics, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201 and  Cell Signaling Technology Inc., Beverly, Massachusetts 01915

Received for publication, September 24, 2002, and in revised form, January 16, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The Ras-GRF1 exchange factor, which is regulated by increases in intracellular calcium and the release of Gbeta gamma subunits from heterotrimeric G proteins, plays a critical role in the activation of neuronal Ras. Activation of G protein-coupled receptors stimulates an increase in the phosphorylation of Ras-GRF1 at certain serine residues. The first of these sites to be identified, Ser916 in the mouse sequence (equivalent to Ser898 in the rat sequence), is required for full activation of the Ras exchange factor activity of Ras-GRF1 by muscarinic receptors. We demonstrate here that Ras-GRF1 is highly expressed in rat brain compared with the Sos exchange factor and that there is an increase in incorporation of 32P into Ser898 of brain Ras-GRF1 following activation of protein kinase A. Phosphorylation of Ras-GRF1 at Ser916 is also required for maximal induction of Ras-dependent neurite outgrowth in PC12 cells. A novel antibody (termed 2152) that selectively recognizes Ras-GRF1 when it is phosphorylated at Ser916/898 confirmed the regulated phosphorylation of Ras-GRF1 by Western blotting in both model systems of transfected COS-7 and PC12 cells and also of the endogenous protein in rat forebrain slices. Indirect confocal immunofluorescence of transfected PC12 cells using antibody 2152 demonstrated reactivity only under conditions in which Ras-GRF1 was phosphorylated at Ser916/898. Confocal immunofluorescence of cortical slices of rat brain revealed widespread and selective phosphorylation of Ras-GRF1 at Ser898. In the prefrontal cortex, there was striking phosphorylation of Ras-GRF1 in the dendritic tree, supporting a role for Ras activation and signal transduction in neurotransmission in this area.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The Ras GTPases are timed molecular switches that cycle between GDP- and GTP-bound forms to control pathways of cellular growth and differentiation (1). In addition to the well established roles for Ras in the proliferation of normal and malignant cells (2), there is increasing evidence that Ras also regulates critical functions in terminally differentiated cells such as neurons (3). The GTPase cycle is controlled by guanine nucleotide exchange factors (GEFs)1 and GTPase-activating proteins (GAPs) (4), with the balance between the effective GEF and GAP activities determining the activation state of Ras because it is the GTP-bound form that activates downstream effector pathways. The principal control in many instances may be the activation process through the activity or subcellular localization of the GEF, as there is increasing evidence that these Ras activators are highly regulated (5). In other cases, such as type 1 neurofibromatosis, where there is loss of the Ras-GAP activity of the protein neurofibromin (6), physiological control is shown to require the deactivation step. Indeed, oncogenic mutations in Ras that block the GAP-catalyzed deactivation of Ras from the GTP- to GDP-bound states (7), emphasize the importance of this switch mechanism.

The Ras-GRF1 exchange factor (8), which is also termed CDC25Mm (9, 10), is highly expressed in neurons of the central nervous system (11-13). Ras-GRF1 is expressed predominantly at synapses (14), a neuronal subcellular distribution it shares with the Ras-GAP termed SynGap (15). This colocalization suggests that the proteins may reciprocally regulate Ras at synapses. Interestingly, Ras (16) and the Ras effector mitogen-activated protein kinase (17, 18) have been implicated in the control of synaptic plasticity, which is the proposed cellular corollary of memory storage, whereas mice that lack Ras-GRF1 have defects in memory (19, 20). Thus, Ras-GRF1 may participate in the regulation of synaptic plasticity in the central nervous system.

Ras-GRF1 couples heterotrimeric G proteins (21-24) and calcium signals (8, 25) to the activation of Ras. The activation of Ras-GRF1 by G protein-coupled receptors is closely associated with an increase in its phosphorylation at certain serine residues (24), with the first of these to be identified being Ser916 (in the mouse sequence, equivalent to Ser898 in the rat sequence) (26). Phosphorylation of Ser916/898, which is an in vivo and in vitro substrate for protein kinase A (PKA), is necessary for full activation of the Ras-GEF activity of Ras-GRF1 (26). The current study confirms that Ser916/898 is a physiologically relevant site of regulated phosphorylation in the endogenous Ras-GRF1 exchange factor that is expressed in rat forebrain. Localization of this regulatory phosphorylation event to the apical dendrites of prefrontal pyramidal cells suggests that Ras signaling is activated at these loci.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Plasmids and Transfection-- Constructs in the pKH3 mammalian expression vector (27) that encode murine Ras-GRF1, Ras-GRF1Delta N, Ras-GRF1Delta 900, and the S916A mutant have previously been described (23, 26). Ras-GRF1Delta 976 was prepared by PCR using a 5'-primer with a BamHI restriction site from the template pKH3Ras-GRF1Delta N and verified by sequencing. Mammalian expression vectors for rat Ras-GRF1 (8), Sos1 (28), Myc-tagged H-Ras (29), and muscarinic receptor subtypes 1 and 2 (30) were generously provided by Profs. L .A. Feig, M. Czech, J. Jackson, and M. R. Brann, respectively. COS-7 cells were transfected by calcium phosphate coprecipitation (27), and PC12 cells by electroporation (31).

Expression of recombinant wild-type Ras-GRF1-(900-983) and Ras-GRF1-(900-983) with the S916A mutation as fusion proteins with glutathione S-transferase (GST) has been previously described (26). GST-Ras-GRF1-(632-1262) (equivalent to GST-GRF1Delta N) was expressed from the vector pGEX.GRF1-(632-1262), which was constructed by subcloning the BamHI/EcoRI insert from pKH3GRF1Delta N (23) into pGEX-2T.

Metabolic Labeling and Digestion of Ras-GRF1-- Forebrain slices cut from postnatal day 15 rat brains were labeled in six-well tissue culture plates in 1 ml/well phosphate-free Dulbecco's modified Eagle's medium (Invitrogen) with 2 mCi of [32P]orthophosphate (ICN, Costa Mesa, CA) for 2 h in a 37 °C incubator that was supplied with 95% O2 and 5% CO2. The slices were lysed, and Ras-GRF1 was immunoprecipitated using antibody sc-224 (Santa Cruz Biotechnology, Santa Cruz, CA) as described (23). Immunoprecipitated labeled Ras-GRF1 was processed for Western blotting and digestion with cyanogen bromide as described (26).

Development of Polyclonal Antibody 2152 against Ras-GRF1 Ser(P)916-- Antibodies were developed in rabbits immunized with a 13-residue phosphopeptide that represents the region flanking Ser916 of mouse Ras-GRF1. This sequence is highly conserved (with only three conservative substitutions) in rat Ras-GRF1 (8). The specificity of the antibodies was tested, and affinity-purified antibody 2152 was characterized as a selective agent for recognition of both mouse and rat Ras-GRF1 only when phosphorylated at the relevant serine (see below). Western blots were developed by enhanced chemiluminescent detection (32).

Confocal Immunofluorescence-- Dual labeling indirect confocal immunofluorescence of transfected PC12 cells was performed as previously described (33). For neurite outgrowth experiments, the primary antibodies used were anti-Myc monoclonal antibody 9e10 (1:1000 dilution; Sigma) for detection of cells expressing Myc-H-Ras and anti-hemagglutinin-1 (HA1) polyclonal antibody Y-11 (1:150 dilution; Santa Cruz Biotechnology) for detection of cells expressing HA13-Ras-GRF1. The secondary antibodies used were Cy3-coupled anti-mouse antibody (1:300 dilution; Jackson Laboratories, Bar Harbor, ME) and Oregon Green-coupled anti-rabbit antibody (1:300 dilution; Molecular Probes, Inc., Eugene, OR). Pictures were taken with a ×40 water immersion lens on a Zeiss LSM310 microscope. Neurite outgrowth was quantified as previously described (34). To determine phosphorylation of Ras-GRF1, the procedure was similar, except that the primary antibodies used were anti-HA1 monoclonal antibody 12CA5 (1:500 dilution) for detection of HA13-Ras-GRF1 and polyclonal antibody 2152 (1:300 dilution) for detection of Ras-GRF1 phosphorylated at Ser916/898, and pictures were taken with a ×63 oil immersion lens.

Forebrain slices of postnatal day 15 rat brain were fixed in 4% paraformaldehyde in phosphate-buffered saline and incubated in 50% sucrose/phosphate-buffered saline overnight at 4 °C. The slices were then permeabilized for 10 min with methanol that had been precooled to -20 °C; rinsed with phosphate-buffered saline; and blocked with phosphate-buffered saline containing 2% bovine serum albumen, 5% goat serum, and 0.25% Triton X-100 for 4 h at room temperature. Indirect confocal immunofluorescence was carried out using the following primary polyclonal antibodies: antibody 2152 (anti-Ras-GRF1 Ser(P)916/898; 1:200 dilution); antibody sc-224 (anti-Ras-GRF1; 1:200 dilution); or, as a negative control, antibody sc-863 (anti-Ras-GRF1 antibody that is competent for Western blotting, but does not recognize the protein in immunoprecipitation or immunofluorescence protocols; 1:200 dilution). The secondary antibody used was Oregon Green-coupled anti-rabbit immunoglobulin (1:150 dilution). Pictures were taken with an Olympus Fluoview laser scanning confocal microscope using a ×20 objective.

In Vitro Phosphorylation of Ras-GRF1 Constructs-- GST-GRF1-(900-983) (wild-type and mutant S916A) and GST-GRF1-(632-1262) were reacted with PKA (Sigma) as described (26).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Ras-GRF1 Is Highly Expressed in Rat Brain-- It is now clear that there are multiple GEFs that can serve to activate Ras proteins, including those in the Sos, Ras-GRF1/CDC25Mm, Ras-guanyl nucleotide-releasing protein, and other families (5). Much work has been performed on the ubiquitous Sos exchange factors that activate Ras in response to stimulation of tyrosine kinase-mediated signals (28, 35, 36). In contrast, Ras-GRF1 is expressed predominantly in the neurons of the central nervous system (11-13) and activates Ras in response to G protein-coupled and calcium signals (8, 21-24). To examine the relative expression levels of Sos and Ras-GRF1 in rat brain, a quantitative Western blot protocol was developed. Ras-GRF1 and Sos1 were expressed in COS-7 cells with identical triple-HA1 epitope tags at their N termini. The lysates from these transfections were standardized by Western blotting with anti-HA1 monoclonal antibody 12CA5. The standardized HA13-Ras-GRF1 and HA13-Sos1 lysates were then used to establish the relative sensitivities of two polyclonal antibodies directed against the Ras-GRF1 and Sos proteins (Fig. 1). The polyclonal antibodies detected significantly more Ras-GRF1 than Sos in lysates of rat brain forebrain, even though the sensitivity of the anti-Sos antibody is greater. Correcting for the sensitivity of the antibodies, we found that there was 11-fold more Ras-GRF1 than Sos in rat forebrain slices.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Ras-GRF1 is expressed at a higher level compared with Sos in rat forebrain slices. Lysates of COS-7 cells expressing HA13-Ras-GRF1 and HA13-Sos1 were subjected to Western blotting with the anti-HA1 monoclonal antibody (left panels) and standardized by dilution such that equivalent levels of the expressed proteins were present. These amounts were then run in parallel with lysates of rat brain slices (right panels) and subjected to Western blotting with polyclonal antibodies to either Ras-GRF1 (upper right panel) or Sos (lower right panel). In all cases, a graded scale of four 3-fold dilutions of the lysates was loaded to ensure that the signals could be measured in a range where the signals were not saturated. Data shown are representative of four independent experiments and were collected digitally using a Fuji Film LAS-1000 Plus imaging system. Quantification was performed with ImageGauge Version 3.3 software.

Ras-GRF1 Is Phosphorylated at Ser898 in Forskolin-treated Slices of Rat Brain-- Ras-GRF1 is regulated by a complex of mechanisms that include regulated phosphorylation of serine residues (24). Phosphorylation of Ser916, which is an in vivo substrate for PKA, has been shown to be necessary in model systems for full activation of the Ras-GEF activity of Ras-GRF1 by muscarinic receptors (26). To test whether phosphorylation of this residue also occurs in endogenous Ras-GRF1, we metabolically labeled rat forebrain slices with [32P]orthophosphate, stimulated the slices with forskolin to activate PKA, and immunoprecipitated Ras-GRF1. Ras-GRF1 was then cleaved at methionine residues using cyanogen bromide, and the fragments were separated by peptide PAGE (Fig. 2). Phosphorylation of mouse Ras-GRF1 at Ser916 produces a 32P-labeled fragment with an apparent mobility of ~6.5 kDa (26). The positions of the methionines that flank this phosphorylation site are conserved between mouse and rat. Transfection of COS-7 cells with rat Ras-GRF1 demonstrated that the equivalent phosphorylation (at Ser898) was revealed in a similarly sized cyanogen bromide cleavage product. Stimulation of forebrain slices of rat brain with forskolin induced the appearance of 32P in the equivalent fragment of endogenous Ras-GRF1, confirming that Ser898 is a site of regulated phosphorylation in the brain.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Cyanogen bromide digests of Ras-GRF1 reveal the phosphopeptide that reflects Ser898 phosphorylation in forskolin-treated COS-7 cells and rat forebrain slices. COS-7 cells transfected with pMT3gluGRF1 (8) and rat forebrain slices were labeled with 32Pi and then treated with dimethyl sulfoxide vehicle (-) or 100 µM isobutylmethylxanthine (IBMX) plus 20 µM forskolin (FSK) (+). The Ras-GRF1 proteins were immunoprecipitated and digested with cyanogen bromide, and the fragments were separated by SDS-PAGE using a Tricine cathode buffer to sharpen resolution of the phosphopeptides (26). The results shown are autoradiographs of a region of the dried gels, with molecular mass markers (in kilodaltons) shown to the left. Exposure times were overnight for the COS-7 cell-derived samples and 2 weeks with intensifying screens for the brain-derived samples. The arrow indicates a phosphopeptide fragment that was stimulated by the activation of PKA and represents phosphorylation of Ser898 (26). The result is representative of three independent experiments.

Phosphorylation of Ras-GRF1 at Ser916 Promotes Ras-dependent Outgrowth of Neurites in PC12 Cells-- We have previously shown that phosphorylation of Ras-GRF1 at Ser916 is necessary for maximal activation of Ras-GEF activity in a biochemical assay with recombinant Ras substrate (26). Because we have shown here that this phosphorylation event occurred in the endogenous exchange factor in the brain, we investigated whether this phosphorylation plays a critical role in Ras activation in a neuronal context. We used the well established model of neurite extension from PC12 cells in response to Ras activation (37). The results show that expression of either the C-terminal half of Ras-GRF1 (Ras-GRF1Delta N) or a Myc-tagged H-Ras protein alone did not induce neurite outgrowth (Fig. 3). It has previously been demonstrated that wild-type Ras proteins (those without a constitutively activating, oncogenic mutation) are not sufficient to induce neurite outgrowth (37), and this result further suggests that the Ras-GRF1Delta N protein is not able to activate the endogenous Ras protein in PC12 cells to induce neurite extension. Because H-Ras is the preferred in situ substrate for Ras-GRF1 (29), we assayed for neurite extension in cotransfections of Ras-GRF1Delta N and wild-type H-Ras and found robust outgrowth. Deletion of the Ras-GRF1 construct to leave the C-terminal third (Ras-GRF1Delta 900), although removing the Ras exchange motif sequence that is common to Ras-GEFs (5), did not reduce the H-Ras-dependent induction of neurite outgrowth. Further deletion to leave the C-terminal quarter of Ras-GRF1 (Ras-GRF1Delta 976) did, however, significantly reduce neurite extension. This deletion leaves intact the CDC25 Ras-GEF domain that is necessary for biochemical activity (38) and so reveals a stimulatory function within residues 900-975 of Ras-GRF1. The same reduction in neurite extension was produced by point mutation of the Ser916 phosphorylation site to alanine (Fig. 3).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 3.   Phosphorylation of Ras-GRF1 at Ser916 promotes Ras-dependent outgrowth of neurites in PC12 cells. PC12 cells were transfected by electroporation and then grown for 48 h before processing for indirect confocal immunofluorescence using red detection for the Myc epitope tags at the N termini of the wild-type H-Ras constructs and green detection for the HA1 epitope tags at the N termini of the Ras-GRF1 constructs. Results shown in A-F are representative red fluorescence results (except for E, where green fluorescence is shown) from transfections with GRF1Delta N plus H-Ras (A), GRF1Delta 900 plus H-Ras (B), GRF1Delta 900(S916A) (GRF1Delta 900,916A) plus H-Ras (C), GRF1Delta 976 plus H-Ras (D), GRF1Delta N alone (E), and H-Ras alone (F). Scale bar = 20 µm. Neurite extension was quantified in the red fluorescence channel by measuring the projections that were longer than the diameter of the cell body. In all cases where cotransfections were performed, clear signals in both the red and green channels were required for a cell to be scored. Four independent experiments were performed, with 25 positive cells measured from each trial. Results for the longest neurite produced and for the sum of all neurites are presented in G and H as means ± S.D. Mutation of Ser916 or deletion of residues 900-975 from Ras-GRF1 significantly reduced both parameters of neurite outgrowth (p < 0.001).

Development of an Antibody That Selectively Recognizes Ras-GRF1 Ser(P)916/898-- The appearance of the 32P-labeled fragment of Ras-GRF1 following cyanogen bromide cleavage provides an assay for the regulated phosphorylation of Ser916/898. This assay is time-consuming and provides poor sensitivity, however. To develop a more sensitive and powerful assay approach, antibodies that selectively recognize the Ser(P)916/898 form of Ras-GRF1 were developed. To confirm the selectivity of antibody 2152, it was tested against recombinant Ras-GRF1 proteins that were subjected to phosphorylation by PKA (Fig. 4). The data show that antibody 2152 exhibited great selectivity for recognition of Ras-GRF1 only when it was phosphorylated, with detectable signal produced from as little as 10 ng of Ras-GRF1 Ser(P)916, whereas unphosphorylated Ras-GRF1 was only detected when microgram quantities were present. Note that PKA treatment of the S916A mutant protein did not produce any reactivity to antibody 2152. 


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Antibody 2152 selectively recognizes Ras-GRF1 Ser(P)916. Recombinant GST fusion proteins of the indicated regions of Ras-GRF1 were incubated with (+) or without (-) PKA in the presence of ATP/Mg2+ and then separated by SDS-PAGE on two gels run in parallel. A, one gel was transferred to nitrocellulose and subjected to Western blotting with antibody 2152. Note that reactivity was seen only when the GST-Ras-GRF1 constructs were phosphorylated by PKA and was not seen when Ser916 was mutated to alanine (916A). B, the other gel was stained with Coomassie Blue to confirm the relative loading of the recombinant proteins. C, experiments were repeated with graded loading of the unphosphorylated (open symbols) and phosphorylated (closed symbols) substrates to establish the degree to which antibody 2152 recognizes Ras-GRF1 only when it is phosphorylated at Ser916. Data shown were collected digitally from Western blots using the Fuji Film LAS-1000 Plus imaging system and analyzed with ImageGauge Version 3.3. software. wt, wild-type.

Regulated Phosphorylation of Ras-GRF1 at Ser916/898-- To test whether antibody 2152 recognizes both mouse and rat Ras-GRF1 expressed in mammalian cells, it was tested against whole cell lysates of COS-7 cells that had been transfected to express Ras-GRF1 and then treated with various agonists (Fig. 5). The data show that antibody 2152 reacted with a single band that was present only in the cells transfected to express Ras-GRF1 and that this band had the same mobility as that recognized by an independent anti-Ras-GRF1 antibody (sc-863). Furthermore, it is clear that the recognition of the mouse and rat Ras-GRF1 proteins was similar and that all recognition was absolutely dependent on phosphorylation at Ser916/898, as no reactivity occurred in cells expressing Ras-GRF1(S916A). Both forskolin and serum (the latter to a lesser extent, which is clearer when the Western blots were given prolonged exposure) stimulated an increase in the phosphorylation of Ras-GRF1 at Ser916/898. Interestingly, treatment of the cells with thapsigargin, which increases cytosolic calcium levels (39), failed to increase phosphorylation of Ras-GRF1 at Ser916/898 above the basal level. This result supports previous observations on transfected fibroblasts that increases in calcium do not stimulate the phosphorylation of Ras-GRF1 (40), although it has been reported that Ras-GRF1 is an in vitro substrate for calmodulin-dependent kinase II (14).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5.   Regulated phosphorylation of Ras-GRF1 at Ser916/898 in COS-7 cells. COS-7 cells were transfected with pKH3Ras-GRF1 (to express wild-type mouse Ras-GRF1 (mGRF1 wt)), pKH3Ras-GRF1(S916A) (to express mouse Ras-GRF1(S916A) (mGRF1 916A)), pMT3gluRas-GRF1 (to express wild-type rat Ras-GRF1 (rGRF1 wt)), or an empty vector control (-). The cells were deprived of serum overnight and then stimulated with 100 µM IBMX plus 20 µM forskolin, with 10% fetal calf serum, or with 200 nM thapsigargin. Whole cell extracts were prepared for Western blotting with a 1:2000 dilution of affinity-purified antibody 2152 (upper panel), which showed a strong increase in phosphorylation upon forskolin treatment. Prolonged exposure (middle panel) revealed a low level of basal phosphorylation that was increased by serum stimulation, but not by thapsigargin. The blot was then stripped (69) and reprobed for total Ras-GRF1 proteins using antibody sc-863 (lower panel) to demonstrate the reproducibility of the transfection and loading. Data shown are representative of three independent experiments. anti-GRF1[916phospho], anti-Ras-GRF1 Ser(P)916.

Multiple Agonists Stimulate the Phosphorylation of Ras-GRF1 at Ser916/898 in PC12 Cells-- To investigate the phosphorylation of Ras-GRF1 in a neuronal context, we coexpressed Ras-GRF1 with muscarinic receptors in PC12 cells. Western blotting of PC12 cell lysates (Fig. 6) demonstrated that activation of muscarinic receptors by carbachol, stimulation of PKA by forskolin, and activation of endogenous Trk receptors by nerve growth factor (NGF) all increased the phosphorylation of Ras-GRF1 at Ser916. To extend these results, either HA13-Ras-GRF1 or its S916A mutant was coexpressed in PC12 cells with muscarinic receptors, and the cells were stimulated and then fixed and processed for indirect confocal immunofluorescence (Fig. 7). It is clear that antibody 2152 reactivity was again dependent on phosphorylation at Ser916, as no reactivity was seen in untransfected cells, in transfected cells that were not stimulated, or in stimulated cells that were transfected with the Ras-GRF1(S916A) mutant. In agreement with the Western blot results, carbachol, forskolin, and NGF all induced the phosphorylation of Ras-GRF1 at Ser916.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 6.   Regulated phosphorylation of Ras-GRF1 at Ser916 in PC12 cells as revealed by Western blotting. PC12 cells were cotransfected with pKH3Ras-GRF1 plus expression vectors for human muscarinic receptor subtypes 1 and 2. The cells were deprived of serum overnight and then stimulated with 100 µM carbachol, with 100 µM IBMX plus 20 µM forskolin, or with 10 ng/ml NGF. Whole cell extracts were prepared for Western blotting (32) with antibody 2152 (raised against Ras-GRF1 Ser(P)916 (GRF1(phospho916)); right panel) and with antibody sc-863 (raised against total Ras-GRF1; left panel). Data shown are representative of two independent experiments.


View larger version (73K):
[in this window]
[in a new window]
 
Fig. 7.   Regulated phosphorylation of Ras-GRF1 at Ser916 in PC12 cells as revealed by indirect confocal immunofluorescence. PC12 cells were cotransfected with pKH3Ras-GRF1 (left panels) or pKH3Ras-GRF1(S916A) (right panels) plus expression vectors for human muscarinic receptor subtypes 1 and 2. The cells were deprived of serum overnight and then stimulated with 100 µM carbachol, with 100 µM IBMX plus 20 µM forskolin, or with 10 ng/ml NGF. The cells were fixed and processed for indirect confocal immunofluorescence using red detection for the HA1 epitope tags at the N termini of the Ras-GRF1 constructs and green detection for antibody 2152 (raised against Ras-GRF1 Ser(P)916 (Ras-GRF1phospho916)). The fluorescence images are presented overlaid with a phase-contrast image of the cells that reveals the presence of untransfected control cells. Note that green fluorescence due to antibody 2152 reactivity was found only when wild-type Ras-GRF1 (Ras-GRF1,wt) was present (thus colocalized with red fluorescence and appears yellow) and only in cells that had been stimulated with agonists that induce Ser916 phosphorylation. Data shown are representative of five independent experiments. Ras-GRF1,916A, Ras-GRF1(S916A).

Regulated Phosphorylation of Ras-GRF1 at Ser898 in Rat Forebrain Slices-- To investigate whether endogenous Ras-GRF1 is regulated by phosphorylation in a manner similar to that defined in the model systems, antibody 2152 was used to assess phosphorylation of Ras-GRF1 in rat forebrain slices. It was difficult to detect any reactivity to antibody 2152 in lysates of brain slices by Western blotting, perhaps suggesting that only a subset of Ras-GRF1 proteins (perhaps, in particular, neurons) is phosphorylated at Ser898. When Ras-GRF1 was first immunoprecipitated from the lysate using an antibody directed against the C terminus (sc-224), the regulated phosphorylation at Ser898 became apparent by Western blotting (Fig. 8). There was little reactivity in Ras-GRF1 from untreated slices, but there were clear increases following stimulation with carbachol, forskolin, or NGF. Thus, just as in the expression systems constructed in PC12 cells, endogenous Ras-GRF1 is phosphorylated at Ser898 following activation of muscarinic or Trk receptors or PKA.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 8.   Regulated phosphorylation of endogenous Ras-GRF1 at Ser898 in rat forebrain slices as revealed by Western blotting. Rat forebrain slices were stimulated with 100 µM carbachol, with 100 µM IBMX plus 20 µM forskolin, or with 10 ng/ml NGF for 20 min at room temperature. Lysates were prepared, with 2.5% reserved for direct analysis. Ras-GRF1 was immunoprecipitated from 97.5% of the lysate using antibody sc-224; the immunoprecipitates were then split, with 10% subjected to Western blotting for total Ras-GRF1 using antibody sc-863 (left panel) and 90% subjected to Western blotting with antibody 2152 (raised against Ras-GRF1 Ser(P)898 (GRF1(phospho898)); right panel). Negative control immunoprecipitations ((-ve) i.p.) were performed with rabbit anti-mouse immunoglobulin (Jackson Laboratories). Data shown are representative of four independent experiments.

To investigate the distribution of Ras-GRF1 Ser(P)898 in the cortex, brain slices were fixed and processed for indirect confocal immunofluorescence with antibodies 2152 (anti-Ras-GRF1 Ser(P)916/898) and sc-224 (anti-Ras-GRF1). Prefrontal cortex includes two classes of neurons, GABAergic interneurons and glutamate-secreting pyramidal cells. The latter class is easily recognizable by its distinctive morphology, including a prominent single apical dendrite that branches in the upper layers. In these immunolocalization studies, we observed expression of Ras-GRF1 throughout pyramidal neurons, including the cell bodies (Fig. 9), whereas phosphorylated Ras-GRF1 was strikingly localized to the apical dendrites of pyramidal cells (Fig. 9).


View larger version (92K):
[in this window]
[in a new window]
 
Fig. 9.   Regulated phosphorylation of endogenous Ras-GRF1 at Ser898 in rat cerebral cortex as revealed by indirect confocal immunofluorescence. Forebrain slices of postnatal day 15 rat brains were fixed and processed for indirect confocal immunofluorescence. The primary antibodies used were as follows: antibody 2152, raised against Ras-GRF1 Ser(P)898 (A, the yellow arrows indicate apical dendrites of pyramidal cells in the medial prefrontal cerebral cortex, and the inset shows a lower magnification view); antibody sc-224, raised against total Ras-GRF1 (B1, the yellow arrows indicate apical dendrites of pyramidal cells in the medial prefrontal cerebral cortex, and the red arrows indicate cell bodies); and antibody sc-863, which recognizes Ras-GRF1 only in Western blot protocols, but not in immunofluorescence and so was used as a staining control (B2).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

This study identifies Ser916/898 of the Ras-GRF1 exchange factor as a target for regulated in vivo phosphorylation in both transfected model systems of COS-7 and PC12 cells and endogenously in rat brain slices. The role of Ras-GRF1 in central neurons is intriguing (41, 42), but confusing, as the phenotypes of mice deficient in Ras-GRF1 are not in complete agreement. Brambilla et al. (19) described Ras-GRF1-deficient mice that were impaired in amygdala-dependent learning and memory tests such as emotional conditioning of memory consolidation. The authors stated that there were no deficits in the Morris water maze test, suggesting that hippocampal function was normal, but did find larger field excitatory postsynaptic potentials upon electrophysiological recording from both the amygdala and hippocampus (19). Subsequent work has detailed the hyperexcitability of hippocampal neurons from these mice (43). Giese et al. (20) described smaller-than-control mice with defects in hippocampus-dependent learning and memory as revealed in contextual discrimination, social transmission of food preference, and Morris water maze tests. A third group of Ras-GRF1-deficient mice, studied by Itier et al. (44), were also found to be small, with evidence that this characteristic is due to a decrease in postnatal insulin-like growth factor I production that is secondary to a reduction in pituitary growth hormone levels. Because pituitary growth hormone is under the control of hypothalamic neurotransmission and Ras-GRF1 is normally expressed in the postnatal hypothalamus, the authors suggested that hypothalamic function may be reduced in their Ras-GRF1-deficient mice, but did not report results from any other tests of neuronal function (44). Nevertheless, there is strong support for the concept that Ras-GRF1 is highly expressed in certain central neurons and has the potential to play critical roles in processes (such as memory) to which Ras signaling has previously been linked (3, 45, 46). In this regard, it is interesting to note that Ras-GRF1 is regulated by cAMP/PKA phosphorylation (26, 47), signaling elements that are thought to play a key role in synaptic plasticity and hence memory storage in the brain (17). The identification of activated Ras-GRF1 in the apical dendrites of prefrontal pyramidal neurons in this study is completely consistent with its postulated role as an integrator of neuronal signal transduction (41, 42).

One possibility that might have resolved the differences in the phenotypes of mice that are deficient in Ras-GRF1 would be variable compensation from the highly homologous Ras-GRF2 protein (48). Recently, however, mice deficient in Ras-GRF2 have been described to have neither an apparent phenotype nor any compensatory changes in the expression of Ras-GRF1 (49). Conversely, Ras-GRF1-deficient mice have no alteration in Ras-GRF2 expression. Furthermore, results from mice doubly deficient in both Ras-GRF1 and Ras-GRF2 were also reported. Remarkably, there is no further phenotypic effect beyond that produced by loss of Ras-GRF1 alone, suggesting that there is no overlap of function between these highly similar GEFs (49). In this regard, it is important to note that the Ser916/898 phosphorylation site, although conserved in Ras-GRF1 proteins from rodents and humans, is absent in Ras-GRF2. Thus, it is plausible that this regulatory mechanism is part of the unique function of Ras-GRF1 that cannot be replaced by Ras-GRF2.

Phosphorylation of Ras-GRF1 at Ser916 has previously been shown to be essential for maximal activation of Ras-GRF1 in a biochemical assay with recombinant Ras substrate (26). In the current study, we have shown that there is a regulatory function for residues 900-975 of Ras-GRF1 to increase Ras activation in the PC12 system and that this function is also lost by point mutation of the Ser916 phosphorylation site. Although Ras-GRF1 is phosphorylated at multiple sites in response to agonist stimulation, Ser916 is the only detectable site of phosphorylation in this region (26). These results therefore support the significance of Ras-GRF1 phosphorylation at Ser916/898 both as a marker for increased Ras activation within a neuronal context and in the physiological control of neuronal Ras activation.

Muscarinic stimulation was previously demonstrated to increase the phosphorylation and activity of Ras-GRF1 in mouse brain explants (23); thus, stimulation of rat brain Ras-GRF1 Ser898 phosphorylation by carbachol treatment was expected. Activation of muscarinic receptor signaling in the cortex is also correlated with memory function in humans (50), with broad pharmacological significance (51). Whether Ras-GRF1 phosphorylation and activation of Ras in response to muscarinic agonists are a physiological part of this process remains to be demonstrated.

The Ser916/898 context fits a consensus PKA substrate sequence (52) and does indeed serve as a PKA site both in vitro and in vivo in model systems (26). Phosphorylation at this site was not, however, recorded in in vitro experiments with PKA and recombinant Ras-GRF1 by Baouz et al. (47). The basis for this difference is unclear, but the current study provides further in vivo support for this PKA-dependent phosphorylation through demonstration of stimulation of Ser916/898 phosphorylation by forskolin treatment. More surprising was the robust ability of NGF to stimulate Ras-GRF1 phosphorylation at Ser916/898 in both the transfected PC12 model and the endogenous protein in rat brain slices. Previously, Ras-GRF1 has generally been found to be regulated independently from growth factor/tyrosine kinase pathways (21, 23), although Ras-GRF1 was reported to associate with the NGF-activated TrkA receptor (53). The current result suggests that the interaction of the TrkA and Ras-GRF1 signaling pathways may be functionally important in those neurons that express both proteins.

In addition to Ras-GEF activity that is stimulated by a G protein beta gamma subunit-dependent pathway and is associated with increased serine phosphorylation (23), Ras-GRF1 has also been demonstrated to exhibit Rac-GEF activity that can be induced by the coexpression of G protein beta gamma subunits and is associated with increased tyrosine phosphorylation (54). Both of these pathways can be induced by the same agonist, lysophosphatidic acid, at least in NIH-3T3 fibroblast model systems (24, 55). Tyrosine phosphorylation of Ras-GRF1 that is induced by v-Src increases Rac-GEF activity, but does not increase Ras-GEF activity (56). In contrast, ACK1-dependent tyrosine phosphorylation of Ras-GRF1 increases Ras-GEF activity, but does not induce Rac-GEF activity (57). These results suggest that there may be multiple sites of tyrosine phosphorylation on Ras-GRF1 with distinct effects. Because ACK1 can couple to both growth factor pathways and the CDC42 small GTPase, it is possible that ACK1 may participate in the interactions between the NGF/TrkA pathway and Ras-GRF1 or between CDC42 and Ras-GRF1 (58, 59). In view of the close parallels between the control of the Ras-GEF and Rac-GEF activities of Ras-GRF1, it is possible that phosphorylation of Ser916/898 may also participate in the control of Rac exchange activity, but this remains unclear.

Ras-GRF1 provides an example for other GEFs that are also subject to complex regulation through phosphorylation (60, 61), allosteric interactions (62-64), and subcellular redistribution (65). The activation of Ras-GRF1 is also complicated by the potential for dimerization and for effects that may be mediated through the activation of Raf, the Ras effector, even in the absence of apparent further activation of Ras (66). It is likely that these complexities reflect the underlying function of Ras-GRF1 and other GEFs to serve as key integrators and controllers of signaling pathways with activities beyond the simple control of GTP binding to their substrates. For example, an emerging model suggests that the GEFs provide a scaffold or framework function that can select the downstream targets of their substrate GTPases (67, 68). Thus, it is essential to consider the cellular and subcellular context within which the GEF acts to activate Ras signal transduction. In this regard, the selectivity and sensitivity of anti-Ras-GRF1 Ser(P)916/898 antibody 2152 will provide a powerful approach toward the elucidation of Ras activation pathways in central neurons.

    ACKNOWLEDGEMENTS

We thank Dr. D. R. Lowy for the original gift of the plasmid encoding CDC25Mm and Drs. M. R. Brann, M. Czech, J. Jackson, and L. A. Feig for gifts of plasmids encoding human muscarinic receptors, Sos1, Myc-tagged H-Ras, and rat Ras-GRF1, respectively. NGF was generously provided by Genentech, Inc. Initial work on the relative expression of Ras-GRF1 and Sos was performed by C. L. Smith in the laboratory of Dr. I. G. Macara. The production of the anti-Ras-GRF1 Ser(P)916 antibody was carried out by Cell Signaling Technology, Inc.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants R01 CA381150 (to R. R. M.) and R01 MH43985 (to R. A.). Work performed at the Cell Imaging and Cytometry Facility Core was supported by NIEHS Center Grants P30 ES06639 and NCI Grant P30 CA22453 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by Initiative for Minority Student Development Grant GM-58905 from the National Institutes of Health.

|| Supported by Cell Signaling Technology, Inc.

§§ To whom correspondence should be addressed: Dept. of Pharmacology, Wayne State University, 540 E. Canfield Ave., Detroit, MI 48201. Tel.: 313-577-6022; Fax: 313-577-6739; E-mail: r.mattingly@wayne.edu.

Published, JBC Papers in Press, January 21, 2003, DOI 10.1074/jbc.M209805200

    ABBREVIATIONS

The abbreviations used are: GEF, guanine nucleotide exchange factor; GAP, GTPase-activating protein; PKA, protein kinase A; GST, glutathione S-transferase; HA1, hemagglutinin-1; NGF, nerve growth factor; IBMX, isobutylmethylxanthine; Tricine, N-[2-hydroxy-1, 1-bis(hydroxymethyl)ethyl]glycine.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Macara, I. G., Lounsbury, K. M., Richards, S. A., McKiernan, C., and Bar-Sagi, D. (1996) FASEB J. 10, 625-630[Abstract/Free Full Text]
2. Barbacid, M. (1987) Annu. Rev. Biochem. 56, 779-827[CrossRef][Medline] [Order article via Infotrieve]
3. Rosen, L. B., Ginty, D. D., Weber, M. J., and Greenberg, M. E. (1994) Neuron 12, 1207-1221[Medline] [Order article via Infotrieve]
4. Boguski, M. S., and McCormick, F. (1993) Nature 366, 643-654[CrossRef][Medline] [Order article via Infotrieve]
5. Quilliam, L. A., Rebhun, J. F., and Castro, A. F. (2002) Prog. Nucleic Acids Res. Mol. Biol. 71, 391-444[Medline] [Order article via Infotrieve]
6. DeClue, J. E., Cohen, B. D., and Lowy, D. R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9914-9918[Abstract]
7. Trahey, M., and McCormick, F. (1987) Science 238, 542-545[Medline] [Order article via Infotrieve]
8. Shou, C., Farnsworth, C. L., Neel, B. G., and Feig, L. A. (1992) Nature 358, 351-354[CrossRef][Medline] [Order article via Infotrieve]
9. Cen, H., Papageorge, A. G., Vass, W. C., Zhang, K. E., and Lowy, D. R. (1993) Mol. Cell. Biol. 13, 7718-7724[Abstract]
10. Martegani, E., Vanoni, M., Zippel, R., Coccetti, P., Brambilla, R., Ferrari, C., Sturani, E., and Alberghina, L. (1992) EMBO J. 11, 2151-2157[Abstract]
11. Wei, W., Schreiber, S. S., Baudry, M., Tocco, G., and Broek, D. (1993) Brain Res. Mol. Brain Res. 19, 339-344[Medline] [Order article via Infotrieve]
12. Ferrari, C., Zippel, R., Martegani, E., Gnesutta, N., Carrera, V., and Sturani, E. (1994) Exp. Cell Res. 210, 353-357[CrossRef][Medline] [Order article via Infotrieve]
13. Zippel, R., Gnesutta, N., Matus-Leibovitch, N., Mancinelli, E., Saya, D., Vogel, Z., Sturani, E., Renata, Z., Nerina, G., Noa, M. L., Enzo, M., Daniella, S., Zvi, V., and Emmapaola, S. (1997) Brain Res. Mol. Brain Res. 48, 140-144[CrossRef][Medline] [Order article via Infotrieve]
14. Sturani, E., Abbondio, A., Branduardi, P., Ferrari, C., Zippel, R., Martegani, E., Vanoni, M., and Denis-Donini, S. (1997) Exp. Cell Res. 235, 117-123[CrossRef][Medline] [Order article via Infotrieve]
15. Chen, H. J., Rojas-Soto, M., Oguni, A., and Kennedy, M. B. (1998) Neuron 20, 895-904[Medline] [Order article via Infotrieve]
16. Zhu, J. J., Qin, Y., Zhao, M., Van Aelst, L., and Malinow, R. (2002) Cell 110, 443-455[Medline] [Order article via Infotrieve]
17. Bailey, C. H., Bartsch, D., and Kandel, E. R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13445-13452[Abstract/Free Full Text]
18. Patterson, S. L., Pittenger, C., Morozov, A., Martin, K. C., Scanlin, H., Drake, C., and Kandel, E. R. (2001) Neuron 32, 123-140[Medline] [Order article via Infotrieve]
19. Brambilla, R., Gnesutta, N., Minichiello, L., White, G., Roylance, A. J., Herron, C. E., Ramsey, M., Wolfer, D. P., Cestari, V., Rossi-Arnaud, C., Grant, S. G., Chapman, P. F., Lipp, H. P., Sturani, E., and Klein, R. (1997) Nature 390, 281-286[CrossRef][Medline] [Order article via Infotrieve]
20. Giese, K. P., Friedman, E., Telliez, J. B., Fedorov, N. B., Wines, M., Feig, L. A., and Silva, A. J. (2001) Neuropharmacology 41, 791-800[CrossRef][Medline] [Order article via Infotrieve]
21. Shou, C., Wurmser, A., Suen, K. L., Barbacid, M., Feig, L. A., and Ling, K. (1995) Oncogene 10, 1887-1893[Medline] [Order article via Infotrieve]
22. Zippel, R., Orecchia, S., Sturani, E., and Martegani, E. (1996) Oncogene 12, 2697-2703[Medline] [Order article via Infotrieve]
23. Mattingly, R. R., and Macara, I. G. (1996) Nature 382, 268-272[CrossRef][Medline] [Order article via Infotrieve]
24. Mattingly, R. R., Saini, V., and Macara, I. G. (1999) Cell. Signal. 11, 603-610[CrossRef][Medline] [Order article via Infotrieve]
25. Buchsbaum, R., Telliez, J. B., Goonesekera, S., and Feig, L. A. (1996) Mol. Cell. Biol. 16, 4888-4896[Abstract]
26. Mattingly, R. R. (1999) J. Biol. Chem. 274, 37379-37384[Abstract/Free Full Text]
27. Mattingly, R. R., Sorisky, A., Brann, M. R., and Macara, I. G. (1994) Mol. Cell. Biol. 14, 7943-7952[Abstract]
28. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. (1993) Nature 363, 45-51[CrossRef][Medline] [Order article via Infotrieve]
29. Jones, M. K., and Jackson, J. H. (1998) J. Biol. Chem. 273, 1782-1787[Abstract/Free Full Text]
30. Bonner, T. I., Buckley, N. J., Young, A. C., and Brann, M. R. (1987) Science 237, 527-532[Medline] [Order article via Infotrieve]
31. McKiernan, C. J., Stabila, P. F., and Macara, I. G. (1996) Mol. Cell. Biol. 16, 4985-4995[Abstract]
32. Mattingly, R. R., Felczak, A., Chen, C. C., McCabe, M. J., Jr., and Rosenspire, A. J. (2001) Toxicol. Appl. Pharmacol. 176, 162-168[CrossRef][Medline] [Order article via Infotrieve]
33. Lounsbury, K. M., Richards, S. A., Carey, K. L., and Macara, I. G. (1996) J. Biol. Chem. 271, 32834-32841[Abstract/Free Full Text]
34. Yang, H., Xiao, Z.-c., Becker, B., Hillenbrand, R., Rougon, G., and Schachner, M. (1999) J. Neurosci. Res. 55, 687-701[CrossRef][Medline] [Order article via Infotrieve]
35. Corbalan-Garcia, S., Margarit, S. M., Galron, D., Yang, S. S., and Bar-Sagi, D. (1998) Mol. Cell. Biol. 18, 880-886[Abstract/Free Full Text]
36. Innocenti, M., Tenca, P., Frittoli, E., Faretta, M., Tocchetti, A., Di Fiore, P. P., and Scita, G. (2002) J. Cell Biol. 156, 125-136[Abstract/Free Full Text]
37. Bar-Sagi, D., and Feramisco, J. R. (1985) Cell 42, 841-848[Medline] [Order article via Infotrieve]
38. Coccetti, P., Monzani, E., Alberghina, L., Casella, L., and Martegani, E. (1998) Biochim. Biophys. Acta 1383, 292-300[Medline] [Order article via Infotrieve]
39. Mattingly, R. R., and Garrison, J. C. (1992) FEBS Lett. 296, 225-230[CrossRef][Medline] [Order article via Infotrieve]
40. Mattingly, R. R. (1998) In Vitro Mol. Toxicol. 11, 57-62
41. Finkbeiner, S., and Dalva, M. B. (1998) Bioessays 20, 691-695[CrossRef][Medline] [Order article via Infotrieve]
42. Orban, P. C., Chapman, P. F., and Brambilla, R. (1999) Trends Neurosci. 22, 38-44[CrossRef][Medline] [Order article via Infotrieve]
43. Tonini, R., Franceschetti, S., Parolaro, D., Sala, M., Mancinelli, E., Tininini, S., Brusetti, R., Sancini, G., Brambilla, R., Martegani, E., Sturani, E., and Zippel, R. (2001) Mol. Cell. Neurosci. 18, 691-701[CrossRef][Medline] [Order article via Infotrieve]
44. Itier, J. M., Tremp, G. L., Leonard, J. F., Multon, M. C., Ret, G., Schweighoffer, F., Tocque, B., Bluet-Pajot, M. T., Cormier, V., and Dautry, F. (1998) Nature 393, 125-126[CrossRef][Medline] [Order article via Infotrieve]
45. Costa, R. M., Federov, N. B., Kogan, J. H., Murphy, G. G., Stern, J., Ohno, M., Kucherlapati, R., Jacks, T., and Silva, A. J. (2002) Nature 415, 526-530[CrossRef][Medline] [Order article via Infotrieve]
46. Weeber, E. J., and Sweatt, J. D. (2002) Neuron 33, 845-848[Medline] [Order article via Infotrieve]
47. Baouz, S., Jacquet, E., Accorsi, K., Hountondji, C., Balestrini, M., Zippel, R., Sturani, E., and Parmeggiani, A. (2001) J. Biol. Chem. 276, 1742-1749[Abstract/Free Full Text]
48. Fam, N. P., Fan, W. T., Wang, Z., Zhang, L. J., Chen, H., and Moran, M. F. (1997) Mol. Cell. Biol. 17, 1396-1406[Abstract]
49. Fernandez-Medarde, A., Esteban, L. M., Nunez, A., Porteros, A., Tessarollo, L., and Santos, E. (2002) Mol. Cell. Biol. 22, 2498-2504[Abstract/Free Full Text]
50. Bartus, R. T., Dean, R. L., III, Beer, B., and Lippa, A. S. (1982) Science 217, 408-414[Medline] [Order article via Infotrieve]
51. Messer, W. S., Jr. (2002) Curr. Top. Med. Chem. 2, 353-358[Medline] [Order article via Infotrieve]
52. Pearson, R. B., and Kemp, B. E. (1991) Methods Enzymol. 200, 62-81[Medline] [Order article via Infotrieve]
53. MacDonald, J. I., Verdi, J. M., and Meakin, S. O. (1999) J. Mol. Neurosci. 13, 141-158[Medline] [Order article via Infotrieve]
54. Kiyono, M., Satoh, T., and Kaziro, Y. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 4826-4831[Abstract/Free Full Text]
55. Innocenti, M., Zippel, R., Brambilla, R., and Sturani, E. (1999) FEBS Lett. 460, 357-362[CrossRef][Medline] [Order article via Infotrieve]
56. Kiyono, M., Kaziro, Y., and Satoh, T. (2000) J. Biol. Chem. 275, 5441-5446[Abstract/Free Full Text]
57. Kiyono, M., Kato, J., Kataoka, T., Kaziro, Y., and Satoh, T. (2000) J. Biol. Chem. 275, 29788-29793[Abstract/Free Full Text]
58. Arozarena, I., Aaronson, D. S., Matallanas, D., Sanz, V., Ajenjo, N., Tenbaum, S. P., Teramoto, H., Ighishi, T., Zabala, J. C., Gutkind, J. S., and Crespo, P. (2000) J. Biol. Chem. 275, 26441-26448[Abstract/Free Full Text]
59. Arozarena, I., Matallanas, D., and Crespo, P. (2001) J. Biol. Chem. 276, 21878-21884[Abstract/Free Full Text]
60. Fleming, I. N., Elliott, C. M., Buchanan, F. G., Downes, C. P., and Exton, J. H. (1999) J. Biol. Chem. 274, 12753-12758[Abstract/Free Full Text]
61. Ichiba, T., Hashimoto, Y., Nakaya, M., Kuraishi, Y., Tanaka, S., Kurata, T., Mochizuki, N., and Matsuda, M. (1999) J. Biol. Chem. 274, 14376-14381[Abstract/Free Full Text]
62. Ebinu, J. O., Bottorff, D. A., Chan, E. Y., Stang, S. L., Dunn, R. J., and Stone, J. C. (1998) Science 280, 1082-1086[Abstract/Free Full Text]
63. Hart, M. J., Jiang, X., Kozasa, T., Roscoe, W., Singer, W. D., Gilman, A. G., Sternweis, P. C., and Bollag, G. (1998) Science 280, 2112-2114[Abstract/Free Full Text]
64. Pak, Y., Pham, N., and Rotin, D. (2002) Mol. Cell. Biol. 22, 7942-7952[Abstract/Free Full Text]
65. Buday, L., and Downward, J. (1993) Cell 73, 611-620[Medline] [Order article via Infotrieve]
66. Anborgh, P. H., Qian, X., Papageorge, A. G., Vass, W. C., DeClue, J. E., and Lowy, D. R. (1999) Mol. Cell. Biol. 19, 4611-4622[Abstract/Free Full Text]
67. Giglione, C., and Parmeggiani, A. (1998) J. Biol. Chem. 273, 34737-34744[Abstract/Free Full Text]
68. Buchsbaum, R. J., Connolly, B. A., and Feig, L. A. (2002) Mol. Cell. Biol. 22, 4073-4085[Abstract/Free Full Text]
69. Mattingly, R. R., Milstein, M. L., and Mirkin, B. L. (2001) Cell. Signal. 13, 499-505[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.